BioSpace News Archive

ONL Therapeutics, Inc. announced today that David Esposito, chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Monday, February 6, 2023, at 2:00 p.m. ET.

Anavex Life Sciences Corp. today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 ( blarcamesine ) EXCELLENCE Phase 2/3 study in Rett syndrome patients ages ≥ 5 years to 17 (inclusive).

Tango Therapeutics , Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.

Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets.

Theralase® Technologies Inc. announced today that its Phase II Bacillus Calmette Guerin (“ BCG ”) Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”) (Interim) data has been accepted by the American Urology Association (“AUA”) for a moderated poster presentation at its annual meeting.

DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Tuesday, February 28, 2023, at 8:30 am ET to review its fourth quarter and full year 2022 financial results.

First Wave BioPharma, Inc. today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

Purple Biotech Ltd. today announced that it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment.